作者: Liang Ma , Joseph A. Kovacs
DOI: 10.1128/AAC.44.11.3092-3096.2000
关键词:
摘要: Dihydrofolate reductase (DHFR) is the target of trimethoprim (TMP), which has been widely used in combination with sulfa drugs for treatment and prophylaxis Pneumocystis carinii pneumonia. While rat-derived P. DHFR well characterized, kinetic studies human-derived DHFR, differs from by 38% amino acid sequence, have not reported to date. Here we report on expression characterization recombinant DHFR. The 618-bp coding sequence gene was expressed Escherichia coli. As determined sodium dodecyl sulfate-polyacrylamide gel eletrophoresis, purified enzyme had a molecular mass 25 kDa, consistent that predicted DNA sequence. Kinetic analysis showed K(m) values dihydrofolate NADPH were 2.7 +/- 0.3 14.0 4.3 microM, respectively, are similar those Inhibition revealed both TMP pyrimethamine poor inhibitors K(i) 0.28 0.08 0.065 0.005 while trimetrexate methotrexate potent inhibitors, 0.23 0.03 0.016 0.004 nM, respectively. availability large quantities should facilitate identification antifolate greater potency higher selectivity